Agency for Care Effectiveness (ACE) ads

ACE conducts technical evaluations to assess the effectiveness, safety, and value of health technologies (such as drugs, vaccines, and medical devices) to inform the Ministry of Health (MOH) advisory committees when they make funding recommendations. From October 2025 to the end of January 2026, patients, carers, and representatives from patient or voluntary organisations can submit applications to suggest which health technologies ACE should evaluate for funding. Read our factsheet to learn more about how patients can be involved and contact your patient organisation for an application form: https://go.gov.sg/aceli395. #ACEInAction

Many people with chronic coronary heart disease (also known as chronic coronary syndrome) take antiplatelet medicines such as aspirin, clopidogrel, or ticagrelor, to lower their risk of a heart attack. Learn the common myths and facts about antiplatelet medicines in our patient education aid: go.gov.sg/aceli397 Singapore Heart Foundation (SHF) #mythorfact #patienteducation #ACE #CareMadeSimple

Most people with osteoporosis don't realise they have it until they break a bone. The good news is, it’s never too late to take action. Simple steps can help strengthen your bones and lower your risk of fractures. Find out more about osteoporosis and the injectable treatments available for it in our factsheet: https://go.gov.sg/aceli386 #ACE #patienteducation

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare condition caused by abnormal protein build-up in the heart muscles. Over time, these protein deposits can cause the heart muscles to become thick and stiff, making it hard for the heart to pump blood effectively to the rest of the body. This may eventually lead to heart failure and repeated hospital stays. When Mr S, a retiree, was diagnosed with ATTR-CM, he began treatment with tafamidis. But treatment costs were high – over $10,000 every month. Following ACE’s health technology assessment and value-based pricing negotiations for tafamidis, the MOH Drug Advisory Committee (DAC) recommended this treatment for government subsidy. This has made tafamidis more affordable for Mr S, enabling him to access effective and value-based care. Stay aligned with ACE’s technology guidance on tafamidis for treating ATTR-CM: https://go.gov.sg/aceli393 #AgencyForCareEffectiveness #VoicesOfValue #PatientStories

📢 Calling all healthcare professionals! Do you have a clinical topic that you would like to see developed into an ACE Clinical Guideline (ACG)? ACE’s annual ACG topic call is now open! 🗓️ Submission period: 6 October to 14 November 2025 ACE invites healthcare professionals across both public and private institutions to submit your topic for ACE-MOH consideration for guideline development in 2027. All submissions will be reviewed by the Evidence to Practice Advisory Committee (ETPAC) and prioritised based on factors such as their impact on health outcomes and cost; potential for clinical- and cost-effectiveness; alignment with national health priorities, as well as regulatory and policy considerations. Click to start your online submission: https://go.gov.sg/aceli379 Browse our current ACG pipeline here: https://go.gov.sg/aceli380 #ACE #ACEHTA #ETPO #Healthcare #clinicalguidelines #ACG #guidelinedevelopment #ACGtopiccall

ACE conducts technical evaluations to assess the effectiveness, safety, and value of health technologies — such as drugs, vaccines, and medical devices — to inform the Ministry of Health (MOH) advisory committees when they make funding recommendations. From October 2025 until the end of January 2026, patients, carers, and representatives from patient or voluntary organisations can submit applications to suggest which health technologies ACE should evaluate for funding. Read our factsheet to learn more about how patients can be involved and contact your patient organisation for an application form: go.gov.sg/aceli375